on 30 Apr 2024
Last Applicant/ Owned by
11099 North Torrey Pines Road, Suite 280
La Jolla
US
92037
Serial Number
97716174 filed on 13th Dec 2022
Registration Number
N/A
Correspondent Address
Alyssa M. WorshamWILSON SONSINI GOORICH & ROSATI
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Research and development in the field of covalent protein biologics; medical and scientific research in the field of cancer treatment and diagnosis; pharmaceutical research and development; research and development of pharmaceuticals and biologicals in the field of cancer therapeutics; research and development in the field of synthetic biology enabled covalent therapeutics and covalent protein druRead More
Research and development in the field of covalent protein biologics; medical and scientific research in the field of cancer treatment and diagnosis; pharmaceutical research and development; research and development of pharmaceuticals and biologicals in the field of cancer therapeutics; research and development in the field of synthetic biology enabled covalent therapeutics and covalent protein drugs; research and development for the purpose of selective covalent modification of proteins; research and development in the field of oncology, namely, development of a biotechnology platform to create covalent protein biologics for treating cancer; research and development in the field of covalent protein drugs, namely, development of a platform technology for identification of small-molecule and biologic therapeutics for treating cancer and targeting tumors; conducting clinical trials for others in the field of cancer therapeutics; biotechnology testing services, namely, testing in the field of recombinant protein production and bioconjugation; research and development services in the field of antibody-drug conjugates, T cells, natural killer (NK) cells, and macrophage engaging antibodies; research and development services for the purpose of antibody engineering, namely, custom design and engineering of antibodies
Pharmaceutical products, preparations, and substances for the treatment of cancer; cancer therapeutics, namely, anti-cancer preparations; novel cancer therapies, namely, pharmaceutical preparations and substances for the treatment of cancer and tumors; biological preparations and substances for the treatment, diagnosis, detection, and prevention of cancer; pharmaceutical products consisting of covalent protein biologic for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; pharmaceutical products, namely, covalent protein drugs for the treatment of cancer diseases; pharmaceuticals products consisting of synthetic biology enabled covalent protein biologic for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; pharmaceutical products consisting of covalent protein drugs for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals
Reagents for medical research, namely, for therapeutic drug development; antibody reagents for scientific purposes; in-vivo diagnostic reagents for scientific or research use; enzymes for scientific use; cell culture media for use in scientific research for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; active chemical ingredients for use in the manufacture of anti-cancer drugs; laboratory chemicals, namely, an antibody reagent used for the detection of cancerous tumors; antibodies for research use, namely, for therapeutic drug development
No 97716174
No Service Mark
No 60801-TM1001
No
No
No
No
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 30th Apr 2024 | OICIAL GAZETTE PUBLICATION CONIRMATION E-MAILE |
| 30th Apr 2024 | PUBLISHE OR OPPOSITION |
| 10th Apr 2024 | NOTIICATION O NOTICE O PUBLICATION E-MAILE |
| 27th Mar 2024 | APPROVE OR PUB - PRINCIPAL REGISTER |
| 22nd Mar 2024 | TEAS RESPONSE TO OICE ACTION RECEIVE |
| 22nd Mar 2024 | CORRESPONENCE RECEIVE IN LAW OICE |
| 22nd Mar 2024 | TEAS/EMAIL CORRESPONENCE ENTERE |
| 13th Jan 2024 | NOTIICATION O NON-INAL ACTION E-MAILE |
| 13th Jan 2024 | NON-INAL ACTION E-MAILE |
| 13th Jan 2024 | NON-INAL ACTION WRITTEN |
